A Clinical Trial of TQC3721 Suspension for Inhalation
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721
suspension for inhalation in single/multiple administration(s) in healthy subjects; to
evaluate the safety,tolerability and efficacy TQC3721 suspension for inhalation in multiple
administrations in patients with Chronic Obstructive Pulmonary Disease（COPD）and asthma.